

References

- Abrams, K. (1998) Monitoring randomised controlled trials. Parkinson's disease trial illustrates the dangers of stopping early. *British Medical Journal*, **316** 1183–4.
- Abrams, K. and Sansó, B. (1998) Approximate Bayesian inference for random effects meta-analysis. *Statistics in Medicine*, **17**, 201–18.
- Abrams, K., Ashby, D. and Errington, D. (1994) Simple Bayesian analysis in clinical trials – a tutorial. *Controlled Clinical Trials*, **15**, 349–59.
- Adar, R., Critchfield, G. C. and Eddy, D. M. (1989) A confidence profile analysis of the results of femoropopliteal percutaneous transluminal angioplasty in the treatment of lower-extremity ischemia. *Journal of Vascular Surgery*, **10**, 57–67.
- Ades, A. E. and Cliffe, S. (2002) Markov chain Monte Carlo estimation of a multi-parameter decision model: Consistency of evidence and the accurate assessment of uncertainty. *Medical Decision Making*, **22**, 359–71.
- Albert, J. (1996) *Bayesian Computation Using Minitab*. Wadsworth, Belmont, CA.
- Albert, J. and Chib, S. (1996) Bayesian modelling of binary repeated measures data with application to crossover trials. In *Bayesian Biostatistics* (D. A. Berry and D. K. Stangl, eds), pp. 577–600. Marcel Dekker, New York.
- Allen-Mersh, T. G., Earlam, S., Fordy, C., Abrams, K. and Houghton, J. (1994) Quality-of-life and survival with continuous hepatic-artery floxuridine infusion for colorectal liver metastases. *Lancet*, **344**, 1255–60.
- Altman, D. G. (1994) Discussion of 'Bayesian approaches to randomised trials' by Spiegelhalter *et al.* *Journal of the Royal Statistical Society, Series A*, **157**, 387–416.
- Altman, D. G. (2001). *Practical Statistics for Medical Research* (2nd edition) Chapman & Hall/CRC, Boca Raton, FL.
- Altman, D. G., Babiker, A., Campbell, M. K., Clemens, F., Darbyshire, J., Elbourne, D., Grant, A. M., McLeer, S. K., Parmar, M., Pocock, S., Spiegelhalter, D. J., Walker, M. and Wallace, S. (2004) Issues in data monitoring and interim analysis of trials. *Health Technology Assessment*, **8**. To appear.
- Anscombe, F. (1963) Sequential medical trials. *Journal of the American Statistical Association*, **58**, 365–83.
- Arends, L., Hoes, A., Lubsen, J., Grobbee, D. and Stijnen, T. (2000) Baseline risk as predictor of treatment benefit: three clinical meta-re-analyses. *Statistics in Medicine*, **19**, 3497–518.
- Armitage, P. (1985) The search for optimality in clinical trials. *International Statistical Review*, **53**, 15–24.
- Armitage, P. (1989) Inference and decision in clinical trials. *Journal of Clinical Epidemiology*, **42**, 293–9.

- Armitage, P. (1990) Discussion of 'Biostatistics and Bayes' by Breslow. *Statistical Science*, **5**(3).
- Armitage, P. (1991a) Interim analysis in clinical trials. *Statistics in Medicine*, **10**, 925–37.
- Armitage, P. (1991b) Letter to the editor. *Controlled Clinical Trials*, **12**, 345.
- Armitage, P. (1993) A case for Bayesianism in clinical trials – discussion. *Statistics in Medicine*, **12**, 1395–404.
- Armitage, P., McPherson, C. K. and Rowe, B. C. (1969) Repeated significance tests on accumulating data. *Journal of the Royal Statistical Society, Series A*, **132**, 235–44.
- Ashby, D. and Hutton, J. (1996) Bayesian epidemiology. In *Bayesian Biostatistics* (D. A. Berry and D. K. Stangl, eds), pp. 109–38. Marcel Dekker, New York.
- Ashby, D. and Smith, A. (2000) Evidence-based medicine as Bayesian decision-making. *Statistics in Medicine*, **19**, 3291–305.
- Ashby, D., Hutton, J. and McGee, M. (1993) Simple Bayesian analyses for case-control studies in cancer epidemiology. *Statistician*, **42**, 385–97.
- Ayanian, J., Landrum, M., Normand, S., Guadagnoli, E. and McNeil, B. (1998) Rating the appropriateness of coronary angiography – do practicing physicians agree with an expert panel and with each other? *New England Journal of Medicine*, **338**, 1896–1904.
- Baraff, L. J., Oslund, S. and Prather, M. (1993) Effect of antibiotic therapy and etiologic microorganism on the risk of bacterial meningitis in children with occult bacteremia. *Pediatrics*, **92**, 140–3.
- Barnett, V. (1982). *Comparative Statistical Inference* (2nd edition). John Wiley & Sons, Ltd, Chichester.
- Bather, J. A. (1985) On the allocation of treatments in sequential medical trials. *International Statistical Review*, **53**, 1–13.
- Baudoin, C. and O'Quigley, J. (1994) Symmetrical intervals and confidence intervals. *Biometrical Journal*, **36**, 927–34.
- Baum, M., Houghton, J., Riley, D., MacIntyre, J., Berstock, D., McKinna, A., Jackson, I., Sainsbury, J. R. C., Wilson, A., Wheeler, T., Dobbs, J., Rees, G., Powles, T., Rubens, R., Haybittle, J., McPherson, K. and Houghton, J. (1992) Results of the cancer-research campaign adjuvant trial for perioperative cyclophosphamide and long-term tamoxifen in early breast-cancer reported at the 10th year of follow-up. *Acta Oncologica*, **31**, 251–7.
- Bayes, T. (1763). An essay towards solving a problem in the doctrine of chances. *Philosophical Transactions of the Royal Society*, **53**, 418.
- Begg, C. B. (1989) Comments on 'Investigating therapies of potentially great benefit: ECMO' by J H Ware. *Statistical Science*, **4**, 320–2.
- Begg, C. B. (1992). Book review of 'Cross Design Synthesis'. *Statistics in Medicine*, **12**, 1627–30.
- Begg, C. B., DuMouchel, W., Harris, J., Dobson, A., Dear, K., Givens, G. H., Smith, D. D. and Tweedie, R. L. (1997) Publication bias in meta-analysis: a Bayesian data-augmentation approach to account for issues exemplified in the passive smoking debate – comments and rejoinders. *Statistical Science*, **12**, 241–50.
- Belin, T. R., Elashoff, R. M., Leung, K., Nisembaum, R., Bastani, R., Nasseri, K. and Maxwell, A. (1995) Combining information from multiple sources in the analysis of non-equivalent control group design. In *Case Studies in Bayesian Statistics, Volume II* (C. Gatsonis, J. Hodges, R. Kass, and N. Singpurwalla, eds), pp. 241–60. Springer-Verlag, New York.
- Ben-Shlomo, Y., Churchyard, A., Head, J., Hurwitz, B., Overstall, P., Ockelford, J. and Lees, A. J. (1998) Investigation by Parkinson's Disease Research Group of United Kingdom into excess mortality seen with combined levodopa and selegiline treatment

- in patients with early, mild Parkinson's disease: further results of randomised trial and confidential inquiry. *British Medical Journal*, **316**, 1191–6.
- Bennett, C. C., Johnson, A., Field, D. J. and Elbourne, D. (2001) UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation: follow-up to age 4 years. *Lancet*, **357**, 1094–6.
- Benson, B. and Hartz, A. (2000) A comparison of observational studies and randomized controlled trials. *New England Journal of Medicine*, **342**, 1878–86.
- Berger, J. (1985) *Statistical Decision Theory and Bayesian Inference*. Springer-Verlag, Berlin.
- Berger, J. and Berry, D. A. (1988) Statistical analysis and the illusion of objectivity. *American Scientist*, **76**, 159–65.
- Berger, J. and Wolpert, R. (1988) *The Likelihood Principle* (2nd edition) Institute of Mathematical Statistics, Hayward, CA.
- Bergman, S. and Gittins, J. (eds) (1985) *Statistical Methods for Pharmaceutical Research Planning*. Marcel Dekker, New York.
- Bernardinelli, L., Clayton, D., Pascutto, C., Montomoli, C., Ghislandi, M. and Songini, M. (1995) Bayesian analysis of space–time variation in disease risk. *Statistics in Medicine*, **14**, 2433–43.
- Bernardo, J. M. and Smith, A. F. M. (1994) *Bayesian Theory*. John Wiley & Sons, Ltd, Chichester.
- Berry, D. A. (1987) Interim analysis in clinical trials – the role of the likelihood principle. *American Statistician*, **41**, 117–22.
- Berry, D. A. (1989a) Comments on 'Investigating therapies of potentially great benefit: ECMO' by J H Ware. *Statistical Science*, **4**, 306–10.
- Berry, D. A. (1989b) Monitoring accumulating data in a clinical trial. *Biometrics*, **45**, 1197–1211.
- Berry, D. A. (1991) Bayesian methods in phase III trials. *Drug Information Journal*, **25**, 345–68.
- Berry, D. A. (1993) A case for Bayesianism in clinical trials. *Statistics in Medicine*, **12**, 1377–93.
- Berry, D. A. (1994) Discussion of 'Bayesian approaches to randomised trials' by Spiegelhalter *et al.* *Journal of the Royal Statistical Society, Series A*, **157**, 387–416.
- Berry, D. A. (1995) Decision analysis and Bayesian methods in clinical trials. *Cancer Treatment Research*, **75**, 125–54.
- Berry, D. A. (1996a) *Statistics: A Bayesian Perspective*. Duxbury Press, Belmont, CA.
- Berry, D. A. (1996b) When is a confirmatory randomised clinical trial needed? *Journal of the National Cancer Institute*, **88**, 1606–7.
- Berry, D. A. (2001) Adaptive clinical trials and Bayesian statistics in drug development (with discussion). *Biopharmaceutical Report*, **9**(2), 1–11.
- Berry, D. A. and Eick, S. G. (1995) Adaptive assignment versus balanced randomization in clinical trials – a decision analysis. *Statistics in Medicine*, **14**, 231–46.
- Berry, D. A. and Pearson, L. M. (1985) Optimal designs for clinical trials with dichotomous responses. *Statistics in Medicine*, **4**, 597–608.
- Berry, D. A. and Stangl, D. K. (1996a) Bayesian methods in health-related research. In *Bayesian Biostatistics* (D. A. Berry and D. K. Stangl, eds), pp. 3–66. Marcel Dekker, New York.
- Berry, D. A. and Stangl, D. K. (eds) (1996b) *Bayesian Biostatistics*. Marcel Dekker, New York.
- Berry, D. A., Wolff, M. C. and Sack, D. (1994) Decision making during a phase III randomised controlled trial. *Controlled Clinical Trials*, **15**, 360–78.
- Berry, D. A., Mueller, P., Grieve, A., Smith, M., Parke, T., Blazek, R., Mitchard, N., and Krams, M. (2001a). Adaptive Bayesian designs for dose-ranging drug trials. In *Case Studies in Bayesian Statistics, Volume V*, (C. Gatsonis, B. Carlin and A. Carriquiry, eds), pp. 99–181. Springer-Verlag, New York.

- Berry, G., Matthews, J. S. and Armitage, P. (2001b) *Statistics Methods in Medical Research* (4th edition). Blackwell Scientific Publications, Oxford.
- Berry, S. (2000) Meta-analysis versus large trials: resolving the controversy. In *Meta-analysis in Medicine and Health Policy* (D. K. Stangl and D. A. Berry, eds), pp. 65–82. Marcel Dekker, New York.
- Berry, S. and Kadane, J. B. (1997) Optimal Bayesian randomization. *Journal of the Royal Statistical Society, Series B*, **59**, 813–19.
- Biggerstaff, B. J., Tweedie, R. L. and Mengersen, K. L. (1994) Passive smoking in the workplace: classical and Bayesian meta-analyses. *International Archives of Occupational and Environmental Health*, **66**, 269–77.
- Black, N. (1996) Why we need observational studies to evaluate the effectiveness of health care. *British Medical Journal*, **312**, 1215–18.
- Bland, J. M. and Altman, D. G. (1998) Statistics notes: Bayesians and frequentists. *British Medical Journal*, **317**(7166), 1151.
- Box, G. E. P. (1980) Sampling and Bayes' inference in scientific modelling and robustness (with discussion). *Journal of the Royal Statistical Society, Series A*, **143**, 383–430.
- Box, G. E. P. and Tiao, G. C. (1973) *Bayesian Inference in Statistical Analysis*. Addison-Wesley, Reading, MA.
- Brant, L. J., Duncan, D. B. and Dixon, D. O. (1992) K-ratio *t*-tests for multiple comparisons involving several treatments and a control. *Statistics in Medicine*, **11**, 863–73.
- Breslow, N. (1990) Biostatistics and Bayes. *Statistical Science*, **5**, 269–84.
- Briggs, A. (2000) Handling uncertainty in cost-effectiveness models. *Pharmacoeconomics*, **17**, 479–500.
- Briggs, A. and Gray, A. M. (1999) Handling uncertainty when performing economic evaluation of healthcare interventions. *Health Technology Assessment*, **3**(2), 1–134.
- Briggs, A. and Sculpher, M. (1997) Markov models of medical prognosis – commentary. *British Medical Journal*, **314**, 354–5.
- Briggs, A. and Sculpher, M. (1998) An introduction to Markov modelling for economic evaluation. *Pharmacoeconomics*, **13**, 397–409.
- Bring, J. (1995) Stopping a clinical trial early because of toxicity – the Bayesian approach. *Controlled Clinical Trials*, **16**, 131–2.
- Britton, A., Murray, D. W., Bulstrode, C. J., McPherson, K. and Denham, R. A. (1996) Long-term comparison of Charnley and Stanmore design total hip replacements. *Journal of Bone Joint Surgery*, **78B**, 802–8.
- Britton, A., McKee, M., Black, N., McPherson, K., Sanderson, C. and Bain, C. (1998) Choosing between randomised and non-randomised studies: a systematic review. *Health Technology Assessment*, **2**(13), 1–124.
- Brooks, S. P. (1998) Markov chain Monte Carlo method and its application. *The Statistician*, **47**, 69–100.
- Brophy, J. M. and Joseph, L. (1995). Placing trials in context using Bayesian analysis – GUSTO revisited by Reverend Bayes. *Journal of the American Medical Association*, **273**, 871–5.
- Brophy, J. M. and Joseph, L. (1997). Bayesian interim statistical analysis of randomised trials. *Lancet*, **349**, 1166–8.
- Brophy, J. and Joseph, L. (2000) A Bayesian analysis of random mega-trials for the choice of thrombotic agents in acute myocardial infarction. In *Meta-analysis in Medicine and Health Policy* (D. K. Stangl and D. A. Berry, eds), pp. 83–104. Marcel Dekker, New York.
- Brown, B. W., Herson, J., Atkinson, E. N. and Rozell, M. E. (1987) Projection from previous studies – a Bayesian and frequentist compromise. *Controlled Clinical Trials*, **8**, 29–44.
- Brunier, H. C. and Whitehead, J. (1994) Sample sizes for phase II clinical trials derived from Bayesian decision theory. *Statistics in Medicine*, **13**, 2493–502.

- Bryant, J. and Day, R. (2000) Clinical trials and sample size considerations: another perspective – comment. *Statistical Science*, **15**, 106–8.
- Burmester, D. E. and Wilson, A. M. (1996) An introduction to second-order random variables in human health risk assessments. *Human Ecological Risk Assessment*, **2**, 892–919.
- Burton, P. R. (1994) Helping doctors to draw appropriate inferences from the analysis of medical studies. *Statistics in Medicine*, **13**, 1699–1713.
- Burton, P. R., Gurrin, L. C. and Campbell, M. J. (1998) Clinical significance not statistical significance: a simple Bayesian alternative to p values. *Journal of Epidemiology and Community Health*, **52**, 318–23.
- Buxton, M. and Hanney, S. (1998) Evaluating the NHS research and development programme: will the programme give value for money? *Journal of the Royal Society of Medicine*, **91**, 2–6.
- Byar, D. P. (1980) Why data bases should not replace clinical trials. *Biometrics*, **36**, 337–42.
- Byar, D. P., Simon, R. M., Friedewald, W. T., Schlesselman, J. J., DeMets, D. L., Ellenberg, J. H., Gail, M. H. and Ware, J. H. (1976) Randomized clinical trials. Perspectives on some recent ideas. *New England Journal of Medicine*, **295**, 74–80.
- Byar, D. P., Schoenfeld, D. A., Green, S. B., Amato, D. A., Davis, R., De Gruttola, V., Finkelstein, D. M., Gatsonis, C., Gelber, R. D., Lagakos, S. *et al.* (1990) Design considerations for AIDS trials. *New England Journal of Medicine*, **323**, 1343–8.
- Campbell, G. (1999) *A Regulatory Perspective for Bayesian Clinical Trials*. Food and Drug Administration, Rockville, MD.
- Campbell, M., Fitzpatrick, R., Harnes, A., Kinmonth, A.L., Sandercock, P., Spiegelhalter, D. and Tyrer, P. (2000) Framework for design and evaluation of complex interventions to improve health. *British Medical Journal*, **34**, 694–6.
- Carlin, B. P. and Louis, T. A. (2000) *Bayes and Empirical Bayes Methods for Data Analysis* (2nd edition) Chapman & Hall/CRC, Boca Raton, FL.
- Carlin, B. P. and Sargent, D. J. (1996) Robust Bayesian approaches for clinical trial monitoring. *Statistics in Medicine*, **15**, 1093–1106.
- Carlin, B. P., Chaloner, K., Church, T., Louis, T. A. and Matts, J. P. (1993) Bayesian approaches for monitoring clinical trials with an application to toxoplasmic encephalitis prophylaxis. *Statistician*, **42**, 355–67.
- Carlin, B. P., Kadane, J. B. and Gelfand, A. E. (1998) Approaches for optimal sequential decision analysis in clinical trials. *Biometrics*, **54**, 964–75.
- Carlin, J. B. (1992) Meta-analysis for 2×2 tables – a Bayesian approach. *Statistics in Medicine*, **11**, 141–58.
- Carlin, J. B. (2000) Tutorial in biostatistics. Meta-analysis: formulating, evaluating, combining, and reporting – by SLT Normand, *Statistics in Medicine*, **18**, 321–359 (1999). *Statistics in Medicine*, **19**, 753–9.
- Casella, G. and George, E. (1992) Explaining the Gibbs sampler. *American Statistician*, **46**, 167–74.
- Chalmers, I. (1997) What is the prior probability of a proposed new treatment being superior to established treatments? *British Medical Journal*, **314**, 74–5.
- Chaloner, K. (1996) Elicitation of prior distributions. In *Bayesian Biostatistics* (D. A. Berry and D. K. Stangl, eds), pp. 141–56. Marcel Dekker, New York.
- Chaloner, K. and Rhame, F. (2001) Quantifying and documenting prior beliefs in clinical trials. *Statistics in Medicine*, **20**, 581–600.
- Chaloner, K. and Verdinelli, I. (1995) Bayesian experimental design – a review. *Statistical Science*, **10**, 273–304.
- Chaloner, K., Church, T., Louis, T. A. and Matts, J. P. (1993) Graphical elicitation of a prior distribution for a clinical trial. *Statistician*, **42**, 341–53.

- Chelimsky, E., Silberman, G. and Droitcour, J. (1993). Cross design synthesis. *Lancet*, **341**(8843), 498.
- Chessa, A. G., Dekker, R., van Vliet, B., Steyerberg, E. W. and Habbema, J. D. F. (1999) Correlations in uncertainty analysis for medical decision making: an application to heart-valve replacement. *Medical Decision Making*, **19**, 276–86.
- Choi, S. C. and Pepple, P. A. (1989). Monitoring clinical trials based on predictive probability of significance. *Biometrics*, **45**, 317–23.
- Christiansen, C. and Morris, C. (1996). Fitting and checking a two-level Poisson model. In *Bayesian Biostatistics*, (D. A. Berry and D. K. Stangl, eds), pp. 467–502. Marcel Dekker, New York.
- Christiansen, C. and Morris, C. (1997a) Improving the statistical approach to health care provider profiling. *Annals of Internal Medicine*, **127**, 764–8.
- Christiansen, C. and Morris, C. (1997b) Hierarchical Poisson regression modeling. *Journal of the American Statistical Association*, **92**, 618–32.
- Claxton, K. (1999a) Bayesian approaches to the value of information: implications for the regulation of new pharmaceuticals. *Health Economics*, **8**, 269–74.
- Claxton, K. (1999b) The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies. *Journal of Health Economics*, **18**, 341–64.
- Claxton, K. and Posnett, J. (1996) An economic approach to clinical trial design and research priority-setting. *Health Economics*, **5**, 513–24.
- Claxton, K. and Thompson, K. M. (2001) A dynamic programming approach to the efficient design of clinical trials. *Journal of Health Economics*, **20**, 797–822.
- Claxton, K., Lacey, L. F. and Walker, S. G. (2000) Selecting treatments: a decision theoretic approach. *Journal of the Royal Statistical Society, Series A*, **163**, 211–25.
- Claxton, K., Neumann, P. J., Araki, S. and Weinstein, M. C. (2001) Bayesian value-of-information analysis – an application to a policy model of Alzheimer's disease. *International Journal of Technology Assessment in Health Care*, **17**, 38–55.
- Clayton, D. G. and Hills, M. (1993). *Statistical Methods in Epidemiology*. Oxford University Press, Oxford.
- Cole, P. (1979). The evolving case-control study. *Journal of Chronic Diseases*, **32**, 15–27.
- Collins, R., Peto, R., Flather, M. and ISIS-4 Collaborative Group (1995) ISIS-4 – a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. *Lancet*, **345**, 669–85.
- Concato, J., Shah, N. and Horwitz, R. I. (2000) Randomized, controlled trials, observational studies, and the hierarchy of research designs. *New England Journal of Medicine*, **342**, 1887–92.
- Cooper, N. J., Sutton, A. J. and Abrams, K. R. (2002) Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for Caesarean section. *Statistical Methods in Medical Research*, **11**, 491–512.
- Cooper, N., Abrams, K., Sutton, A., Turner, D. and Lambert, P. (2003a) Use of Bayesian methods for Markov modelling in cost-effectiveness analysis: an application to taxane use in advanced breast cancer. *Journal of the Royal Statistical Society, Series A*, **166**.
- Cooper, N. J., Sutton, A. J., Abrams, K. R., Turner, D. and Wailloo, A. (2003b) Comprehensive decision analytical modelling in economic evaluation: A Bayesian approach. *Health Economics*. To appear
- Cooper, N. J., Sutton, A. J., Mugford, M. and Abrams, K. R. (2003c). Use of Bayesian Markov chain Monte Carlo methods to model cost-of-illness data. *Medical Decision Making*, **23** 38–53.

- Cornfield, J. (1966) Sequential trials, sequential analysis and the likelihood principle. *American Statistician*, **20**, 18–23.
- Cornfield, J. (1969) The Bayesian outlook and its applications. *Biometrics*, **25**, 617–57.
- Cornfield, J. (1976) Recent methodological contributions to clinical trials. *American Journal of Epidemiology*, **104**, 408–21.
- Coronary Drug Project Research Group (1970) The Coronary Drug Project. Initial findings leading to a modification of its research protocol. *Journal of the American Medical Association*, **214**, 1301–13.
- Coronary Drug Project Research Group (1975) Clofibrate and niacin in coronary heart disease. *Journal of the American Medical Association*, **231**, 360–81.
- Cox, D. R. (1999) Discussion of 'Some statistical heresies' (Lindsey). *The Statistician*, **48**, 30.
- Cox, D. R. and Farewell, V. T. (1997) Statistical basis of public policy – qualitative and quantitative aspects should not be confused. *British Medical Journal*, **314**, 73.
- Craig, B. A., Fryback, D. G., Klein, R. and Klein, B. E. K. (1999) A Bayesian approach to modelling the natural history of a chronic condition from observations with intervention. *Statistics in Medicine*, **18**, 1355–72.
- Cronin, K. A., Legler, J. M. and Etzioni, R. D. (1998) Assessing uncertainty in micro-simulation modelling with application to cancer screening interventions. *Statistics in Medicine*, **17**, 2509–23.
- Cronin, K. A., Freedman, L. S., Lieberman, R., Weiss, H. L., Beenken, S. W. and Kelloff, G. J. (1999) Bayesian monitoring of phase II trials in cancer chemoprevention. *Journal of Clinical Epidemiology*, **52**, 705–11.
- Daniels, M. J. (1999). A prior for the variance components in hierarchical models. *Canadian Journal of Statistics*, **27**, 569–80.
- de Finetti, B. (1930). Funzione caratteristica di un fenomeno aleatorio. *Memorie dell'Accademia Nazionale dei Lincei*, **4**, 86–133.
- Decisioneering (2000). Crystal Ball. http://www.decisioneering.com/crystal_ball.
- DeGroot, M. H. (1970). *Optimal Statistical Decisions*. McGraw-Hill, New York.
- DeMets, D. and Lan, K. K. G. (1994) Discussion of 'Bayesian approaches to randomised trials' by Spiegelhalter *et al.* *Journal of the Royal Statistical Society, Series A*, **157**, 387–416.
- DeMets, D. L. (1984). Stopping guidelines vs stopping rules – a practitioner's point of view. *Communications in Statistics – Theory and Methods*, **13**, 2395–417.
- Dempster, A. (1998). Bayesian methods. In *Encyclopedia of Biostatistics* (P. Armitage and T. Colton, eds), pp. 263–71. John Wiley & Sons, Ltd, Chichester.
- Dempster, A., Selwyn, M. and Weeks, B. (1983). Combining historical and randomized controls for assessing trends in proportions. *Journal of the American Statistical Association*, **78**, 221–7.
- DerSimonian, R. (1996). Meta-analysis in the design and monitoring of clinical trials. *Statistics in Medicine*, **15**, 1237–48.
- DerSimonian, R. and Laird, N. (1986). Meta-analysis in clinical trials. *Controlled Clinical Trials*, **7**, 177–88.
- Detsky, A. (1985) Using economic analysis to determine the resource consequences of choices made in planning clinical-trials. *Journal of Chronic Diseases*, **38**, 753–65.
- Dignam, J. J., Bryant, J., Wieand, H. S., Fisher, B. and Wolmark, N. (1998) Early stopping of a clinical trial when there is evidence of no treatment benefit: Protocol B-14 of the National Surgical Adjuvant Breast and Bowel Project. *Controlled Clinical Trials*, **19**, 575–88.
- Dixon, D. O. and Simon, R. (1991) Bayesian subset analysis. *Biometrics*, **47**, 871–81.
- Dominici, F. (1998) Testing simultaneous hypotheses in pharmaceutical trials: a Bayesian approach. *Journal of Biopharmaceutical Statistics*, **8**, 283–97.

- Dominici, F., Parmigiani, G., Wolpert, R. and Hasselblad, V. (1999) Meta-analysis of migraine headache treatments: Combining information from heterogeneous designs. *Journal of the American Statistical Association*, **94**, 16–28.
- Donner, A. (1982). A Bayesian approach to the interpretation of subgroup results in clinical trials. *Journal of Chronic Diseases*, **35**, 429–35.
- Dougherty, T. B., Porche, V. H. and Thall, P. F. (2000) Maximum tolerated dose of nalmefene in patients receiving epidural fentanyl and dilute bupivacaine for post-operative analgesia. *Anesthesiology*, **92**, 1010–16.
- Draper, D. (1995) Assessment and propagation of model uncertainty (with discussion). *Journal of the Royal Statistical Society, Series B*, **57**, 45–97.
- Droitcour, J., Silberman, G. and Chelimsky, E. (1993) Cross-design synthesis: a new form of meta-analysis for combining results from randomised clinical trials and medical-practice databases. *International Journal of Technology Assessment in Health Care*, **9**, 440–9.
- DuMouchel, W. (1990). Bayesian meta-analysis. In *Statistical Methodology in the Pharmaceutical Sciences*, (D. Berry, ed.), pp. 509–29. Marcel Dekker, New York.
- DuMouchel, W. and Harris, J. E. (1983) Bayes methods for combining the results of cancer studies in humans and other species (with comment). *Journal of the American Statistical Association*, **78**, 293–308.
- DuMouchel, W. and Normand, S. (2000) Computer-modeling and graphical strategies for meta-analysis. In *Meta-analysis in Medicine and Health Policy* (D. K. Stangl and D. A. Berry, eds), pp. 127–78. Marcel Dekker, New York.
- DuMouchel, W. and Waternaux, C. (1992). Discussion of 'Hierarchical models for combining information and for meta-analyses'. In *Bayesian Statistics 4*, (J. M. Bernardo, J. O. Berger, A. P. Dawid and A. F. M. Smith, eds), pp. 338–41. Clarendon Press, Oxford.
- Dunn, D., Babiker, A., Hooker, M. and Darbyshire, J. (2002) The dangers of inferring treatment effects from observational data: a case study in HIV infection. *Controlled Clinical Trials*, **23**, 106–10.
- Eddy, D. M. (1989). The confidence profile method – a Bayesian method for assessing health technologies. *Operations Research*, **37**, 210–28.
- Eddy, D. M., Hasselblad, V., McGivney, W. and Hendee, W. (1988) The value of mammography screening in women under age 50 years. *Journal of the American Medical Association*, **259**, 1512–19.
- Eddy, D. M., Hasselblad, V. and Shachter, R. (1990a) A Bayesian method for synthesizing evidence: The confidence profile method. *International Journal of Technology Assessment in Health Care*, **6**(1), 31–55.
- Eddy, D. M., Hasselblad, V. and Shachter, R. (1990b). An introduction to a Bayesian method for meta-analysis – the confidence profile method. *Medical Decision Making*, **10**, 15–23.
- Eddy, D. M., Hasselblad, V. and Shachter, R. (1992) *Meta-analysis by the Confidence Profile Method: The Statistical Synthesis of Evidence*. Academic Press, San Diego, CA.
- Edwards, S., Lilford, R., Braunholtz, D. and Jackson, J. (1997) Why 'underpowered' trials are not necessarily unethical. *Lancet*, **350**, 804–7.
- Edwards, S. J. L., Lilford, R. J., Jackson, J. C., Hewison, J. and Thornton, J. (1998) Ethical issues in the design and conduct of randomised controlled trials. *Health Technology Assessment*, **2**(15), 1–132.
- Edwards, W., Lindman, H. and Savage, L. (1963) Bayesian statistical inference for psychological research. *Psychological Review*, **70**, 193–242.
- Ellenberg, S., Fleming, T., and DeMets, D. L. (2002). *Data Monitoring Committees in Clinical Trials: a Practical Perspective*. John Wiley & Sons, Ltd, Chichester.

- Errington, R. D., Ashby, D., Gore, S. M., Abrams, K. R., Myint, S., Bonnett, D. E., Blake, S. W. and Saxton, T. E. (1991) High-energy neutron treatment for pelvic cancers – study stopped because of increased mortality. *British Medical Journal*, **302**, 1045–51.
- Etzioni, R. and Kadane, J. B. (1995) Bayesian statistical methods in public health and medicine. *Annual Review of Public Health*, **16**, 23–41.
- Etzioni, R. and Pepe, M. S. (1994) Monitoring of a pilot toxicity study with 2 adverse outcomes. *Statistics in Medicine*, **13**, 2311–21.
- Fayers, P. (1994) Discussion of 'Bayesian approaches to randomised trials' by Spiegelhalter *et al.* *Journal of the Royal Statistical Society, Series A*, **157**, 387–416.
- Fayers, P. M., Ashby, D. and Parmar, M. K. B. (1997) Tutorial in biostatistics: Bayesian data monitoring in clinical trials. *Statistics in Medicine*, **16**, 1413–30.
- Fayers, P. M., Cuschieri, A., Fielding, J., Craven, J., Uscinska, B. and Freedman, L. S. (2000) Sample size calculation for clinical trials: the impact of clinician beliefs. *British Journal of Cancer*, **82**, 213–9.
- Feinstein, A. R. (1977) Clinical biostatistics XXXIX: The haze of Bayes, the aerial palaces of decision analysis, and the computerised Ouija board. *Clinical Pharmacology and Therapeutics*, **21**, 482–96.
- Felli, J. C. and Hazen, G. B. (1998) Sensitivity analysis and the expected value of perfect information. *Medical Decision Making*, **18**, 95–109.
- Felli, J. C. and Hazen, G. B. (1999). A Bayesian approach to sensitivity analysis. *Health Economics*, **8**, 263–8.
- Field, D., Davis, C., Elbourne, D., Grant, A., Johnson, A., and Macrae, D. (1996). UK collaborative randomised trial of neonatal extracorporeal membrane oxygenation. *Lancet*, **348**, 75–82.
- Fienberg, S. (1992). A brief history of statistics in three and one-half chapters: a review essay. *Statistical Science*, **7**, 208–25.
- Fisher, L. D. (1996). Comments on Bayesian and frequentist analysis and interpretation of clinical trials – comment. *Controlled Clinical Trials*, **17**, 423–34.
- Fitzpatrick, R., Shortall, E., Sculpher, M., Murray, D., Morris, R., Lodge, M., Dawson, J., Carr, A., Britton, A. and Briggs, A. (1998) Primary total hip replacement surgery: a systematic review of outcomes and modelling cost effectiveness associated with different prostheses. *Health Technology Assessment*, **2**(20), 1–64.
- Fletcher, A., Spiegelhalter, D., Staessen, J., Thijs, L. and Bulpitt, C. (1993) Implications for trials in progress of publication of positive results. *Lancet*, **342**, 653–7.
- Fluehler, H., Grieve, A. P., Mandallaz, D., Mau, J. and Moser, H. A. (1983) Bayesian approach to bioequivalence assessment – an example. *Journal of Pharmaceutical Sciences*, **72**, 1178–81.
- Forster, J. J. (1994) A Bayesian approach to the analysis of binary crossover data. *Statistician*, **43**, 61–8.
- Freedman, B. (1987) Equipoise and the ethics of clinical research. *New England Journal of Medicine*, **317**, 141–5.
- Freedman, L. (1996) Bayesian statistical methods – a natural way to assess clinical evidence. *British Medical Journal*, **313**, 569–70.
- Freedman, L. S. and Spiegelhalter, D. J. (1983) The assessment of subjective opinion and its use in relation to stopping rules for clinical trials. *The Statistician*, **32**, 153–60.
- Freedman, L. S. and Spiegelhalter, D. J. (1989) Comparison of Bayesian with group sequential methods for monitoring clinical trials. *Controlled Clinical Trials*, **10**, 357–67.
- Freedman, L. S. and Spiegelhalter, D. J. (1992) Application of Bayesian statistics to decision making during a clinical trial. *Statistics in Medicine*, **11**, 23–35.
- Freedman, L. S., Lowe, D. and Macaskill, P. (1984) Stopping rules for clinical trials incorporating clinical opinion. *Biometrics*, **40**, 575–86.

- Freedman, L. S., Spiegelhalter, D. J. and Parmar, M. K. B. (1994) The what, why and how of Bayesian clinical trials monitoring. *Statistics in Medicine*, **13**, 1371–83.
- Freeman, P. (1993) The role of p -values in analyzing trial results. *Statistics in Medicine*, **12**, 1443–52.
- Frei, A., Cottier, C., Wunderlich, P., and Ludin, E. (1987) Glycerol and dextran combined in the therapy of acute stroke. *Stroke*, **18**, 373–9.
- Freidlin, B., Korn, E. L. and George, S. L. (1999) Data monitoring committees and interim monitoring guidelines. *Controlled Clinical Trials*, **20**, 395–407.
- Fryback, D. G., Chinniss, J. O. and Ulvila, J. W. (2001a). Bayesian cost-effectiveness analysis – an example using the GUSTO trial. *International Journal of Technology Assessment in Health Care*, **17**, 83–97.
- Fryback, D. G., Stout, N. K. and Rosenberg, M. A. (2001b). An elementary introduction to Bayesian computing using WinBUGS. *International Journal of Technology Assessment in Health Care*, **17**, 98–113.
- Gardner, F. J. E., Konje, J. C., Abrams, K. R., Brown, L. J. R., Khanna, S., Al-Azzawi, F., Bell, S. C. and Taylor, D. J. (2000) Endometrial protection from tamoxifen-stimulated changes by a levonorgestrel-releasing intrauterine system: a randomised controlled trial. *Lancet*, **356**, 1711–17.
- Gasparini, M. and Eisele, J. (2000) A curve-free method for phase I clinical trials. *Biometrics*, **56**, 609–15.
- Gatsonis, C. and Greenhouse, J. B. (1992) Bayesian methods for phase I clinical trials. *Statistics in Medicine*, **11**, 1377–89.
- Geddes, J., Freemantle, N., Harrison, P. and Bebbington, P. (2000) Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. *British Medical Journal*, **321**, 1371–6.
- Gelman, A. and Rubin, D. B. (1996) Markov chain Monte Carlo methods in biostatistics. *Statistical Methods in Medical Research*, **5**, 339–55.
- Gelman, A., Carlin, J., Stern, H. and Rubin, D. B. (1995) *Bayesian Data Analysis*. Chapman & Hall, London.
- General Accounting Office (1992) *Cross Design Synthesis: A New Strategy for Medical Effectiveness Research*. General Accounting Office, Washington, DC.
- Genest, C. and Zidek, J. (1986) Combining probability distributions: a critique and an annotated bibliography (with discussion). *Statistical Science*, **1**, 114–48.
- George, S. L., Li, C. C., Berry, D. A. and Green, M. R. (1994) Stopping a clinical trial early – frequentist and Bayesian approaches applied to a CALGB trial in non-small-cell lung cancer. *Statistics in Medicine*, **13**, 1313–27.
- Gilbert, J. P., McPeck, B. and Mosteller, F. (1977) Statistics and ethics in surgery and anesthesia. *Science*, **198**, 684–9.
- Gilks, W. R., Richardson, S. and Spiegelhalter, D. J. (1996) *Markov Chain Monte Carlo in Practice*. Chapman & Hall, London.
- Gittins, J. and Pezeshk, H. (2000) How large should a clinical trial be? *The Statistician*, **49**, 177–87.
- Givens, G. H., Smith, D. D. and Tweedie, R. L. (1997) Publication bias in meta-analysis: a Bayesian data-augmentation approach to account for issues exemplified in the passive smoking debate. *Statistical Science*, **12**, 221–40.
- Goldstein, H. and Spiegelhalter, D. J. (1996) League tables and their limitations: statistical issues in comparisons of institutional performance (with discussion). *Journal of the Royal Statistical Society, Series A*, **159**, 385–443.
- Goodman, S. N. (1999a) Towards evidence-based medical statistics: 1. The P value fallacy. *Annals of Internal Medicine*, **130**, 995–1004.
- Goodman, S. N. (1999b) Towards evidence-based medical statistics: 2. The Bayes factor. *Annals of Internal Medicine*, **130**, 1005–13.

- Goodman, S. N., Zahurak, M. L. and Piantadosi, S. (1995) Some practical improvements in the continual reassessment method for phase I studies. *Statistics in Medicine*, **14**, 1149–61.
- Gore, S. M. (1987) Biostatistics and the Medical Research Council. *Medical Research Council News*.
- Gould, A. L. (1991) Using prior findings to augment active-controlled trials and trials with small placebo groups. *Drug Information Journal*, **25**, 369–80.
- Gould, A. L. (1998) Multi-centre trial analysis revisited. *Statistics in Medicine*, **17**, 1779–97.
- Gray, A., Clarke, P., Farmer, A. and Holman, R. (2002) Implementing intensive control of blood glucose concentration and blood pressure in type 2 diabetes in England: cost analysis (UKPDS 63). *British Medical Journal*, **325**, 860–3.
- Gray, R. J. (1994) A Bayesian analysis of institutional effects in a multicenter cancer clinical trial. *Biometrics*, **50**, 244–53.
- GREAT Group (1992) Feasibility, safety and efficacy of domiciliary thrombolysis by general practitioners: Grampian region early anistreplase trial. *British Medical Journal*, **305**, 548–53.
- Greenhouse, J. B. and Wasserman, L. (1995) Robust Bayesian methods for monitoring clinical trials. *Statistics in Medicine*, **14**, 1379–91.
- Greenland, S. (2000) Principles of multilevel modelling. *International Journal of Epidemiology*, **29**, 158–67.
- Greenland, S. and Robins, J. M. (1991) Empirical-Bayes adjustments for multiple comparisons are sometimes useful. *Epidemiology*, **2**, 244–51.
- Grieve, A. P. (1985) A Bayesian analysis of the two-period crossover design for clinical trials. *Biometrics*, **41**, 979–90.
- Grieve, A. P. (1988) Some uses of predictive distributions in pharmaceutical research. In *Biometry, Clinical Trials and Related Topics*, (T. Okuno, ed.), pp. 83–99. Elsevier Science, Amsterdam.
- Grieve, A. P. (1991) Evaluation of bioequivalence studies. *European Journal of Clinical Pharmacology*, **40**, 201–2.
- Grieve, A. P. (1994a) Bayesian analyses of two-treatment crossover studies. *Statistical Methods in Medical Research*, **3**, 407–29.
- Grieve, A. P. (1994b) Discussion of 'Bayesian approaches to randomised trials'. *Journal of the Royal Statistical Society, Series A*, **157**, 387–416.
- Grieve, A. P. (1995) Extending a Bayesian analysis of the two-period crossover to accommodate missing data. *Biometrika*, **82**, 277–86.
- Grieve, A. P. (1998) Issues for statisticians in pharmaco-economic evaluations. *Statistics in Medicine*, **17**, 1715–23.
- Grieve, A. P. and Senn, S. (1998) Estimating treatment effects in clinical crossover trials. *Journal of Biopharmaceutical Statistics*, **8**, 191–247.
- Grossman, J., Parmar, M. K. B., Spiegelhalter, D. J. and Freedman, L. S. (1994) A unified method for monitoring and analysing controlled trials. *Statistics in Medicine*, **13**, 1815–26.
- Gurrin, L. C., Kurinczuk, J. J. and Burton, P. R. (2000) Bayesian statistics in medical research: an intuitive alternative to conventional data analysis. *Journal of Evaluation of Clinical Practice*, **6**, 193–204.
- Gustafson, P. (1989). Comments on 'Investigating therapies of potentially great benefit: ECMO' by J H Ware. *Statistical Science*, **4**, 310–17.
- Halperin, M., Lan, K. K. G., Ware, J. H., Johnson, N. J. and DeMets, D. L. (1982) An aid to data monitoring in long-term clinical trials. *Controlled Clinical Trials*, **3**, 311–23.

- Halpern, E. F., Weinstein, M. C., Hunink, M. G. M. and Gazelle, G. S. (2000) Representing both first- and second-order uncertainties by Monte Carlo simulation for groups of patients. *Medical Decision Making*, **20**, 314–22.
- Hardy, R. and Thompson, S. (1998) Detecting and describing heterogeneity in meta-analysis. *Statistics in Medicine*, **17**, 841–56.
- Harrell, F. E. and Shih, Y. C. T. (2001) Using full probability models to compute probabilities of actual interest to decision makers. *International Journal of Technology Assessment in Health Care*, **17**, 17–26.
- Hasselblad, V. (1998) Meta-analysis of multi-treatment studies. *Medical Decision Making*, **18**, 37–43.
- Healy, M. (1978) New methodology in clinical trials. *Biometrics*, **34**, 709–12.
- Healy, M. J. R. (1994) Probability and decisions. *American Journal of Diseases in Children*, **71**, 90–4.
- Hedges, L. V. (1998) Bayesian meta-analysis. In *Statistical Analysis of Medical Data: New Developments*, (B. S. Everitt and G. Dunn, eds), pp. 251–76. Arnold, London.
- Heisterkamp, S. H., Doornbos, G. and Gankema, M. (1993) Disease mapping using empirical Bayes and Bayes methods on mortality statistics in The Netherlands. *Statistics in Medicine*, **12**, 1895–1913.
- Heitjan, D. F. (1997) Bayesian interim analysis of phase II cancer clinical trials. *Statistics in Medicine*, **16**, 1791–1802.
- Heitjan, D. F., Moskowitz, A. J. and Whang, W. (1999) Bayesian estimation of cost-effectiveness ratios from clinical trials. *Health Economics*, **8**, 191–201.
- Henderson, W. G., Moritz, T., Goldman, S., Copeland, J. and Sethi, G. (1995) Use of cumulative meta-analysis in the design, monitoring, and final analysis of a clinical trial: a case study. *Controlled Clinical Trials*, **16**, 331–41.
- Herson, J. (1979). Predictive probability early termination for phase II clinical trials. *Biometrics*, **35**, 775–83.
- Higgins, J. P. and Spiegelhalter, D. J. (2002) Being sceptical about meta-analysis: a Bayesian perspective on magnesium trials in myocardial infarction. *International Journal of Epidemiology*, **31**, 96–104.
- Higgins, J. P. and Whitehead, A. (1996) Borrowing strength from external trials in a meta-analysis. *Statistics in Medicine*, **15**, 2733–49.
- Hill, G., Forbes, W., Kozak, J. and MacNeill, I. (2000) Likelihood and clinical trials. *Journal of Clinical Epidemiology*, **53**, 223–7.
- Hilsenbeck, S. G. (1988) Early termination of a phase II clinical trial. *Controlled Clinical Trials*, **9**(3), 177–88.
- Hlatky, M. A. (1991) Using databases to evaluate therapy. *Statistics in Medicine*, **10**, 647–52.
- Hoes, A. W., Grobbee, D. E., Lubsen, J., Tveld, A. J. M. I., Vanderdoes, E. and Hofman, A. (1995) Diuretics, beta-blockers, and the risk for sudden cardiac death in hypertensive patients. *Annals of Internal Medicine*, **123**, 481–7.
- Holland, J. (1962) The Reverend Thomas Bayes, F. R. S. (1702–61). *Journal of the Royal Statistical Society, Series A*, **125**, 451–61.
- Hornberger, J. (2001) Introduction to Bayesian reasoning. *International Journal of Technology Assessment in Health Care*, **17**, 9–16.
- Hornberger, J. and Egghesady, P. (1998) The cost-benefit of a randomised trial to a health care organisation. *Controlled Clinical Trials*, **19**, 198–211.
- Hornberger, J. C., Brown, B. W. and Halpern, J. (1995) Designing a cost-effective clinical trial. *Statistics in Medicine*, **14**, 2249–59.
- Hornbuckle, J., Vail, A., Abrams, K. R. and Thornton, J. G. (2000) Bayesian interpretation of trials: the example of intrapartum electronic fetal heart rate monitoring. *British Journal of Obstetrics and Gynaecology*, **107**, 3–10.

- Howson, C. and Urbach, P. (1989) *Scientific Reasoning: The Bayesian Approach*. Open Court, La Salle, IL.
- Hughes, M. D. (1991) Practical reporting of Bayesian analyses of clinical trials. *Drug Information Journal*, **25**, 381–93.
- Hughes, M. D. (1993) Reporting Bayesian analyses of clinical trials. *Statistics in Medicine*, **12**, 1651–63.
- Human Fertilisation and Embryology Authority (1996) *The Patients' Guide to DI and IVF Clinics* (2nd edition). Human Fertilisation and Embryology Authority, London.
- Hutton, J. L. (1996) The ethics of randomised controlled trials: a matter of statistical belief? *Health Care Analysis*, **4**, 95–102.
- Ibrahim, J. G. and Chen, M. H. (2000) Power prior distributions for regression models. *Statistical Science*, **15**, 46–60.
- International Conference on Harmonisation E9 Expert Working Group (1999) Statistical principles for clinical trials: ICH harmonised tripartite guideline. *Statistics in Medicine*, **18**, 1905–42. See also <http://www.ich.org/ich5e.html>.
- Ioannidis, J. P. A., Haidich, A. B., Pappa, M., Pantazis, N., Kokori, S. I., Tektonidou, M. G., Contopoulos-Ioannidis, D. G. and Lau, J. (2001) Comparison of evidence of treatment effects in randomized and nonrandomized studies. *Journal of the American Medical Association*, **286**, 821–30.
- Jeffreys, H. (1961) *Theory of Probability* (3rd edition). Oxford University Press, Oxford.
- Jennison, C. (1990) Discussion of 'Biostatistics and Bayes' by Breslow. *Statistical Science*, **5**(3).
- Jones, B., Teather, D., Wang, J. and Lewis, J. A. (1998) A comparison of various estimators of a treatment difference for a multi-centre clinical trial. *Statistics in Medicine*, **17**, 1767–77.
- Jones, D. R. (1995) Meta-analysis: weighing the evidence. *Statistics in Medicine*, **14**, 137–49.
- Joseph, L., Duberger, R. and Belisle, P. (1997) Bayesian and mixed Bayesian/likelihood criteria for sample size determination. *Statistics in Medicine*, **16**, 769–81.
- Kadane, J. (1996) *Bayesian Methods and Ethics in a Clinical Trial Design*. John Wiley & Sons, Inc. New York.
- Kadane, J. and Wolfson, L. (1996). Priors for the design and analysis of clinical trials. *Bayesian Biostatistics* (D. A. Berry and D. K. Stangl, eds), pp. 157–84. Marcel Dekker, New York.
- Kadane, J. B. (1995) Prime time for Bayes. *Controlled Clinical Trials*, **16**, 313–18.
- Kadane, J. B., Vlachos, P. and Wieand, S. (1998) Decision analysis for a data monitoring committee of a clinical trial. In *Applied Decision Analysis* (F. J. Girón and M. L. Martínez, eds), pp. 115–21. Kluwer, Boston.
- Kadane, J. B. and Wolfson, L. J. (1997) Experiences in elicitation. *The Statistician*, **46**, 1–17.
- Kass, R. E. and Greenhouse, J. B. (1989) Comments on 'Investigating therapies of potentially great benefit: ECMO' by J H Ware. *Statistical Science*, **4**, 310–17.
- Kass, R. E. and Raftery, A. (1995) Bayes factors and model uncertainty. *Journal of the American Statistical Association*, **90**, 773–95.
- Kass, R. E. and Wasserman, L. (1995) A reference Bayesian test for nested hypotheses and its relationship to the Schwarz criterion. *Journal of the American Statistical Association*, **90**, 928–34.
- Kass, R. E. and Wasserman, L. (1996) The selection of prior distributions by formal rules. *Journal of the American Statistical Association*, **91**, 1343–70.
- Keiding, N. (1994) Discussion of 'Bayesian approaches to randomised trials'. *Journal of the Royal Statistical Society, Series A*, **157**, 387–416.

- Koch, G. G. (1991) Summary and discussion for 'Statistical issues in the pharmaceutical industry: analysis and reporting of phase III clinical trials including kinetic/dynamic analysis and Bayesian analysis'. *Drug Information Journal*, **25**, 433–7.
- Korn, E. L. (1990) Projection from previous studies: a caution [letter; comment]. *Controlled Clinical Trials*, **11**, 67–9.
- Korn, E. L. and Simon, R. (1996) Data monitoring committees and problems of lower than expected accrual or event rates. *Controlled Clinical Trials*, **17**, 526–35.
- Korn, E. L., Yu, K. F. and Miller, L. L. (1993) Stopping a clinical trial very early because of toxicity – summarizing the evidence. *Controlled Clinical Trials*, **14**, 286–95.
- Kunz, R. and Oxman, A. D. (1998) The unpredictability paradox: review of empirical comparisons of randomised and non-randomised clinical trials. *British Medical Journal*, **317**, 1185–90.
- Lachin, J. M. (1981) Sequential clinical trials for normal variates using interval composite hypotheses. *Biometrics*, **37**, 87–101.
- Lan, K. K. G. and Wittes, J. (1988) The B-value – a tool for monitoring data. *Biometrics*, **44**, 579–85.
- Lancet (1992) Cross design synthesis: A new strategy for studying medical outcomes? *Lancet*, **340**, 944–6.
- Lanctot, K. L., and Naranjo, C. A. (1995) Comparison of the Bayesian approach and a simple algorithm for assessment of adverse drug events. *Clinical Pharmacology and Therapeutics*, **58**, 692–8.
- Lang, T. and Secic, M. (1997) Considering 'prior probabilities': reporting Bayesian statistical analyses. In *How to Report Statistics in Medicine* (T. Lang and M. Secic), pp. 231–5. American College of Physicians, Philadelphia.
- Lange, N. and Ryan, L. (1989) Assessing normality in random effects models. *Annals of Statistics*, **17**, 624–42.
- Larose, D. T. and Dey, D. K. (1997) Grouped random effects models for Bayesian meta-analysis. *Statistics in Medicine*, **16**, 1817–29.
- Larsen, K., Petersen, J. H., Budtz-Jørgensen, E. and Endahl, L. (2000). Interpreting parameters in the logistic regression model with random effects. *Biometrics*, **56**, 909–14.
- Lau, J., Schmid, C. H. and Chalmers, T. C. (1995) Cumulative meta-analysis of clinical trials builds evidence for exemplary medical care. *Journal of Clinical Epidemiology*, **48**, 45–57.
- Laupacis, A., Bourne, R., Rorabeck, C., Feeny, D., Wong, C., Tugwell, P., Leslie, K. and Bullas, R. (1993) The effect of elective total hip replacement on health-related quality of life. *Journal of Bone and Joint Surgery*, **75A**, 1619–26.
- Lee, P. M. (1997) *Bayesian Statistics: An Introduction* (2nd edition). Edward Arnold, London.
- Lee, S. J. and Zelen, M. (2000) Clinical trials and sample size considerations: Another perspective. *Statistical Science*, **15**, 95–103.
- Legler, J. M. and Ryan, L. M. (1997) Latent variable models for teratogenesis using multiple binary outcomes. *Journal of the American Statistical Association*, **92**, 13–20.
- Lehmann, H. P. and Goodman, S. N. (2000) Bayesian communication: A clinically significant paradigm for electronic publication. *Journal of the American Medical Informatics Association*, **7**, 254–66.
- Lehmann, H. P. and Nguyen, B. (1997) Bayesian communication of research results over the World Wide Web. *M D Computing*, **14**, 353–9.
- Lehmann, H. P. and Shachter, R. D. (1994) A physician-based architecture for the construction and use of statistical models. *Methods of Information in Medicine*, **33**, 423–32.

- Lewis, J. (1994) Discussion of 'Bayesian approaches to randomized trials'. *Journal of the Royal Statistical Society, Series A*, **157**, 387–416.
- Lewis, R. J. and Wears, R. L. (1993) An introduction to the Bayesian analysis of clinical trials. *Annals of Emergency Medicine*, **22**, 1328–36.
- Li, Z. and Begg, C. B. (1994) Random effects models for combining results from controlled and uncontrolled studies in a meta-analysis. *Journal of the American Statistical Association*, **89**, 1523–7.
- Liao, J. G. (1999) A hierarchical Bayesian model for combining multiple 2×2 tables using conditional likelihoods. *Biometrics*, **55**, 268–72.
- Lilford, R. for the Fetal Compromise Group (1994) Formal measurement of clinical uncertainty: prelude to a trial in perinatal medicine. *British Medical Journal*, **308**, 111–12.
- Lilford, R. J. and Braunholtz, D. (1996) The statistical basis of public policy: a paradigm shift is overdue. *British Medical Journal*, **313**, 603–7.
- Lilford, R. J. and Jackson, J. (1995) Equipoise and the ethics of randomization. *Journal of the Royal Society of Medicine*, **88**, 552–9.
- Lilford, R. J., Thornton, J. G. and Braunholtz, D. (1995) Clinical trials and rare diseases – a way out of a conundrum. *British Medical Journal*, **311**, 1621–5.
- Lindley, D. V. (1957) A statistical paradox. *Biometrika*, **44**, 187–92.
- Lindley, D. V. (1975) The effect of ethical design considerations on statistical analysis. *Applied Statistics*, **24**, 218–28.
- Lindley, D. V. (1985) *Making Decisions* (2nd edition) John Wiley & Sons, Ltd, London.
- Lindley, D. V. (1994) Discussion of 'Bayesian approaches to randomised trials'. *Journal of the Royal Statistical Society, Series A*, **157**, 387–416.
- Lindley, D. V. (1997) The choice of sample size. *Statistician*, **46**, 129–38.
- Lindley, D. V. (1998) Decision analysis and bioequivalence trials. *Statistical Science*, **13**, 136–41.
- Lindley, D. V. (2000) The philosophy of statistics (with discussion). *The Statistician*, **49**, 293–337.
- Lindley, D. V. and Scott, W. F. (1984) *New Cambridge Statistical Tables* (2nd edition). Cambridge University Press, Cambridge.
- Louis, T. A. (1991). Using empirical Bayes methods in biopharmaceutical research. *Statistics in Medicine*, **10**, 811–29.
- Luce, B. R. and Claxton, K. (1999) Redefining the analytical approach to pharmacoeconomics. *Health Economics*, **8**, 187–9.
- Luce, B. R., Shih, Y. C. T. and Claxton, K. (2001) Bayesian approaches to technology assessment and decision making. *International Journal of Technology Assessment in Health Care*, **17**, 1–5.
- Malchau, H. and Herberts, P. (1998). Prognosis of total hip replacement. Revision and re-revision rate in THR: a revision-risk study of 148,359 primary operations. Scientific exhibition presented to the 65th Annual Meeting of the American Academy of Orthopaedic Surgeons, New Orleans.
- Manning, W. G., Fryback, F. G. and Weinstein, M. C. (1996) Reflecting uncertainty in cost-effectiveness analysis. In *Cost Effectiveness in Health and Medicine*, (M. R. Gold, J. R. Siegel, M. C. Weinstein and L. B. Russell, eds), pp. 247–75. Oxford University Press, New York.
- Marshall, E. C. and Spiegelhalter, D. J. (1998) League tables of in-vitro fertilisation clinics: how confident can we be about the rankings? *British Medical Journal*, **317**, 1701–4.
- Marshall, R. J. (1988) Bayesian analysis of case-control studies. *Statistics in Medicine*, **7**, 1223–30.
- Marston, R. A., Cobb, A. G. and Bentley, G. (1996) Stanmore compared with Charnley total hip replacement – a prospective study of 413 arthroplasties. *Journal of Bone and Joint Surgery*, **78B**, 178–84.

- Matchar, D. B., Samsa, G. P., Matthews, J. R., Ancukiewicz, M., Parmigiani, G., Hasselblad, V., Wolf, P. A., D'Agostino, R. B. and Lipscomb, J. (1997) The stroke prevention policy model: linking evidence and clinical decisions. *Annals of Internal Medicine*, **127**, 704–11.
- Matsuyama, Y., Sakamoto, J. and Ohashi, Y. (1998) A Bayesian hierarchical survival model for the institutional effects in a multi-centre cancer clinical trial. *Statistics in Medicine*, **17**, 1893–1908.
- Matthews, J. N. S. (1995) Small clinical trials – are they all bad? *Statistics in Medicine*, **14**, 115–26.
- Matthews, R. (1998). Fact versus factions: the use and abuse of subjectivity in scientific research. Technical report, European Science and Environment Forum, Cambridge.
- Matthews, R. A. J. (2001) Methods for assessing the credibility of clinical trial outcomes. *Drug Information Journal*, **35**, 1469–78.
- McIntosh, M. W. (1996) The population risk as an explanatory variable in research synthesis of clinical trials. *Statistics in Medicine*, **15**, 1713–28.
- McPherson, K. (1982) On choosing the number of interim analyses in clinical trials. *Statistics in Medicine*, **1**, 25–36.
- Mehta, C. R. and Cain, K. C. (1984) Charts for the early stopping of pilot studies. *Journal of Clinical Oncology*, **2**, 676–82.
- Meier, P. (1975) Statistics and medical experimentation. *Biometrics*, **31**, 511–29.
- Miller, M. A. and Seaman, J. W. (1998) A Bayesian approach to assessing the superiority of a dose combination. *Biometrical Journal*, **40**, 43–55.
- Moher, D., Schulz, K. F. and Altman, D. G. (2001) The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. *Lancet*, **357**, 1191–4.
- Morris, C. N. and Normand, S. L. (1992) Hierarchical models for combining information and for meta-analysis. In *Bayesian Statistics 4*, (J. Bernardo, J. O. Berger, D. V. Lindley, and A. F. M. Smith, eds), pp. 321–44. Oxford University Press.
- Morrison, L. J., Verbeck, P. R., McDonald, A. C., Sawadsky, B. V. and Cook, D. J. (2000) Mortality and prehospital thrombolysis for acute myocardial infarction – a meta-analysis. *Journal of the American Medical Association*, **283**, 2686–92.
- Murphy, A. and Winkler, R. (1977) Reliability of subjective probability forecasts of precipitation and temperature. *Applied Statistics*, **26**, 41–7.
- Natarajan, R. and Kass, R. E. (2000) Reference Bayesian methods for generalized linear mixed models. *Journal of the American Statistical Association*, **95**, 227–37.
- New York State Department of Health (1998). *Coronary Artery Bypass Surgery in New York State, 1994–1996*. New York State Department of Health, Albany, NY. <http://www.health.state.ny.us/nysdoh/consumer/heart/homehear.htm>.
- Neyman, J. (1934) On the two different aspects of the representative method: the method of stratified sampling and the method of purposive selection (with discussion). *Journal of the Royal Statistical Society*, **97**, 558–625.
- Neyman, J. (1935) Statistical problems in agricultural experimentation (with discussion). *Supplement to the Journal of the Royal Statistical Society*, **2**, 107–80.
- NICE (2001) *Health Technology Assessment: Guidance for Manufacturers and Sponsors*. National Institute for Clinical Excellence.
- NICE Appraisal Group (2000) The effectiveness and cost effectiveness of different prostheses for primary total hip replacement. Technical report, <http://www.nice.org.uk>.
- Normand, S.-L. T. (1999) Meta-analysis: formulating, evaluating, combining and reporting. *Statistics in Medicine*, **18**, 321–59.
- Normand, S.-L., Glickman, M. E. and Gatsonis, C. A. (1997) Statistical methods for profiling providers of medical care: issues and applications. *Journal of the American Statistical Association*, **92**, 803–14.

- Nurminen, M. and Mutanen, P. (1989) Bayesian analysis of case-control studies. *Statistics in Medicine*, **8**, 1023–4.
- O'Brien, P. C. (1998) Data and safety monitoring. In *Encyclopedia of Biostatistics* (P. Armitage and T. Colton, eds), pp. 1058–66. John Wiley & Sons, Ltd, Chichester.
- O'Hagan, A. (1994) *Kendall's Advanced Theory of Statistics Vol 2B: Bayesian Inference*. Arnold, London.
- O'Hagan, A. and Luce, B. R. (2003) *A Primer on Bayesian Statistics in Health Economics and Outcomes Research*. Centre for Bayesian Statistics in Health Economics, Sheffield. <http://www.shef.ac.uk/~stlao/pdf/primer.pdf>.
- O'Hagan, A. and Stevens, J. W. (2001) A framework for cost-effectiveness analysis from clinical trial data. *Health Economics*, **10**, 303–15.
- O'Hagan, A. and Stevens, J. W. (2002a) Bayesian methods for the design and analysis of cost-effectiveness trials in the evaluation of health care technologies. *Statistical Methods in Medical Research*, **11**, 469–90.
- O'Hagan, A. and Stevens, J. W. (2002b) The probability of cost-effectiveness. *BMC Medical Research Methodology*, **2**(5). <http://biomedcentral.com/1471-2288/2/5>.
- O'Hagan, A., Stevens, J. and Montmartin, J. (2000) Inference for the cost-effectiveness acceptability curve and cost-effectiveness ratio. *Pharmacoeconomics*, **17**, 339–49.
- O'Hagan, A., Stevens, J. W. and Montmartin, J. (2001) Bayesian cost-effectiveness analysis from clinical trial data. *Statistics in Medicine*, **20**, 733–53.
- O'Neill, R. T. (1994) Conclusions: 2. *Statistics in Medicine*, **13**, 1493–9.
- O'Quigley, J. (1992) Estimating the probability of toxicity at the recommended dose following a phase I clinical trial in cancer. *Biometrics*, **48**, 853–62.
- O'Quigley, J., Pepe, M. and Fisher, L. (1990) Continual reassessment method – a practical design for phase I clinical trials in cancer. *Biometrics*, **46**, 33–48.
- O'Rourke, K. (1996) Two cheers for Bayes. *Controlled Clinical Trials*, **17**, 350–2.
- Palisade Europe (2001) @RISK 4.0. Technical report, <http://www.palisade-europe.com>.
- Palmer, C. R. (1993) Ethics and statistical methodology in clinical trials. *Journal of Medical Ethics*, **19**, 219–22.
- Palmer, C. R. (2002) Ethics, data-dependent designs, and the strategy of clinical trials: time to start learning as we go? *Statistical Methods in Medical Research*, **11**, 381–402.
- Palmer, C. R. and Rosenberger, W. F. (1999) Ethics and practice: alternative designs for phase III randomized clinical trials. *Controlled Clinical Trials*, **20**, 172–86.
- Papineau, D. (1994). The virtues of randomisation. *British Journal for the Philosophy of Science*, **45**, 437–50.
- Parmar, M. K. B., Spiegelhalter, D. J. and Freedman, L. S. (1994) The CHART trials: Bayesian design and monitoring in practice. *Statistics in Medicine*, **13**, 1297–312.
- Parmar, M. K. B., Ungerleider, R. S. and Simon, R. (1996) Assessing whether to perform a confirmatory randomised clinical trial. *Journal of the National Cancer Institute*, **88**, 1645–51.
- Parmar, M. K. B., Griffiths, G. O., Spiegelhalter, D. J., Souhami, R. L., Altman, D. G. and van der Scheuren, E. (2001) Monitoring large randomised clinical trials – a new approach using Bayesian methods. *Lancet*, **358**, 375–81.
- Parmigiani, G. (1999). Decision models in screening for breast cancer. In *Bayesian Statistics 6*, (J. Bernardo, J. Berger, A. Dawid, and A. Smith, eds), pp. 525–46. Oxford University Press, Oxford.
- Parmigiani, G. (2002). *Modeling in Medical Decision Making: a Bayesian Approach*. John Wiley & Sons, Ltd, Chichester.
- Parmigiani, G. and Kamlet, M. (1993). A cost-utility analysis of alternative strategies in screening for breast cancer. In *Case Studies in Bayesian Statistics*, (C. Gatsonis, J. Hodges, R. Kass, and N. Singpurwalla, eds), pp. 390–402. Springer-Verlag, Berlin.

- Parmigiani, G., Anckiewicz, M. and Matchar, D. (1996). Decision models in clinical recommendations development: the stroke prevention policy model. In *Bayesian Biostatistics* (D. A. Berry and D. K. Stangl, eds), pp. 207–33. Marcel Dekker, New York.
- Parmigiani, G., Samsa, G. P., Ancukiewicz, M., Lipscomb, J., Hasselblad, V. and Matchar, D. B. (1997). Assessing uncertainty in cost-effectiveness analyses: application to a complex decision model. *Medical Decision Making*, **17**, 390–401.
- Pauler, D. K. and Wakefield, J. (2000) Modeling and implementation in Bayesian meta-analysis. In *Meta-analysis in Medicine and Health Policy* (D. K. Stangl and D. A. Berry, eds), pp. 205–30. Marcel Dekker, New York.
- Pepple, P. A. and Choi, S. C. (1997) Bayesian approach to two-stage phase II trial. *Journal of Biopharmaceutical Statistics*, **7**, 271–86.
- Peto, R. (1985) Discussion of ‘On the allocation of treatments in sequential medical trials’ by J. Bather. *International Statistical Review*, **53**, 1–13.
- Peto, R. and Baigent, C. (1998) Trials: the next 50 years. *British Medical Journal*, **317**, 1170–1.
- Peto, R., Pike, M. C., Armitage, P., Breslow, N. E., Cox, D. R., Howard, S. V., Mantel, N., McPherson, K., Peto, J. and Smith, P. G. (1976) Design and analysis of randomised clinical trials requiring prolonged observation of each patient. I. Introduction and design. *British Journal of Cancer*, **34**, 585–612.
- Pocock, S. (1976) The combination of randomized and historical controls in clinical trials. *Journal of Chronic Diseases*, **29**, 175–88.
- Pocock, S. (1992) When to stop a clinical trial. *British Medical Journal*, **305**, 235–40.
- Pocock, S. (1994) Discussion of ‘Bayesian approaches to randomized trials’. *Journal of the Royal Statistical Society, Series A*, **157**, 387–416.
- Pocock, S. and Hughes, M. D. (1989) Practical problems in interim analyses, with particular regard to estimation. *Controlled Clinical Trials*, **10**, S209–21.
- Pocock, S. and Hughes, M. D. (1990) Estimation issues in clinical trials and overviews. *Statistics in Medicine*, **9**, 657–71.
- Pocock, S. and Spiegelhalter, D. (1992) Domiciliary thrombolysis by general practitioners. *British Medical Journal*, **305**, 1015.
- Pocock, S. and White, I. (1999) Trials stopped early: too good to be true? *Lancet*, **353**, 943–4.
- Prevost, T. C., Abrams, K. R. and Jones, D. R. (2000) Hierarchical models in generalised synthesis of evidence: an example based on studies of breast cancer screening. *Statistics in Medicine*, **19**, 3359–76.
- Qian, J., Stangl, D. and George, S. (1996). A Weibull model for survival data: using prediction to decide when to stop a clinical trial. In *Bayesian Biostatistics* (D. A. Berry and D. K. Stangl, eds), pp. 187–205. Marcel Dekker, New York.
- Racine, A., Grieve, A. P., Fluhler, H. and Smith, A. F. M. (1986) Bayesian methods in practice – experiences in the pharmaceutical industry. *Applied Statistics*, **35**, 93–150.
- Racine-Poon, A. and Wakefield, J. (1996). Bayesian analysis of population pharmacokinetic and instantaneous pharmacodynamic relationships. In *Bayesian Biostatistics* (D. A. Berry and D. K. Stangl, eds), pp. 321–54. Marcel Dekker, New York.
- Raghunathan, T. E. and Siscovick, D. S. (1996) A multiple-imputation analysis of a case-control study of the risk of primary cardiac-arrest among pharmacologically treated hypertensives. *Applied Statistics*, **45**, 335–52.
- Raudenbush, S. W. and Bryk, A. S. (1985) Empirical Bayes meta-analysis. *Journal of Educational Statistics*, **10**, 75–98.
- Reeves, B., MacLehose, R., Harvey, I., Sheldon, T., Russell, I. and Black, A. (2001) A review of observational, quasi-experimental and randomised study designs for the evaluation of the effectiveness of healthcare interventions. In *The Advanced Handbook*

- of *Methods in Evidence Based Healthcare* (A. Stevens, K. Abrams, J. Brazier, R. Fitzpatrick and R. Lilford, eds), pp. 116–35. Sage, London.
- Richards, B., Blandy, J., Bloom, H. G. J. and MRC Bladder Cancer Working Party (1994) The effect of intravesical thiotepa on tumor recurrence after endoscopic treatment of newly-diagnosed superficial bladder cancer – a further report with long-term follow-up of a Medical Research Council randomised trial. *British Journal of Urology*, **73**, 632–8.
- Richardson, S. and Gilks, W. R. (1993) A Bayesian approach to measurement error problems in epidemiology using conditional independence models. *American Journal of Epidemiology*, **138**, 430–42.
- Richardson, S., Monfort, C., Green, M., Draper, G. and Muirhead, C. (1995) Spatial variation of natural radiation and childhood leukaemia incidence in Great Britain. *Statistics in Medicine*, **14**, 2487–501.
- Rittenhouse, B. E. (1997) Exorcising protocol-induced spirits: making the clinical trial relevant for economics. *Medical Decision Making*, **17**, 331–9.
- Rogatko, A. (1992) Bayesian approach for meta-analysis of controlled clinical-trials. *Communications in Statistics – Theory and Methods*, **21**, 1441–62.
- Rosenbaum, P. R. and Rubin, D. B. (1984) Sensitivity of Bayes inference with data-dependent stopping rules. *American Statistician*, **38**, 106–9.
- Rosner, G. L. and Berry, D. A. (1995) A Bayesian group sequential design for a multiple arm randomized clinical trial. *Statistics in Medicine*, **14**, 381–94.
- Royall, R. (1986) The effect of sample size on the meaning of significance tests. *American Statistician*, **40**, 313–15.
- Royall, R. and Berry, D. A. (1989) Comments on 'Investigating therapies of potentially great benefit: ECMO' by J H Ware. *Statistical Science*, **4**, 313–19.
- Rubin, D. (1978) Bayesian inference for casual effects: the role of randomization. *Annals of Statistics*, **7**, 34–58.
- Rubin, D. B. (1992) A new perspective. In *The Future of Meta-analysis*, (D. Rubin, K. Wachter and M. Straf, eds), pp. 155–65. Russell Sage Foundation, New York.
- Russell, L. B. (1999) Modelling for cost-effectiveness analysis. *Statistics in Medicine*, **18**, 3235–44.
- Ryan, L. (1993) Using historical controls in the analysis of developmental toxicity data. *Biometrics*, **49**, 1126–35.
- Samsa, G. P., Reutter, R. A., Parmigiani, G., Ancukiewicz, M., Abrahamse, P., Lipscomb, J. and Matchar, D. B. (1999) Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke. *Journal of Clinical Epidemiology*, **52**, 259–71.
- Sanderson, C., McKee, M., Britton, A., Black, N., McPherson, K. and Bain, C. (2001). Randomised and non-randomised studies: threats to internal and external validity. In *The Advanced Handbook of Methods in Evidence Based Healthcare* (A. Stevens, K. Abrams, J. Brazier, R. Fitzpatrick and R. Lilford, eds), pp. 95–115. Sage, London.
- Sargent, D. and Carlin, B. (1996) Robust Bayesian design and analysis of clinical trials via prior partitioning (with discussion). In *Bayesian Robustness* (J. O. Berger, ed.), IMS Lecture Notes – Monograph Series, 29, pp. 175–93. Institute of Mathematical Statistics, Hayward, CA.
- Sasahara, A., Cole, T., Ederer, F., Murray, J., Wenger, N., Sherry, S. and Stengle, J. (1973) Urokinase Pulmonary Embolism Trial, a national cooperative study. *Circulation*, **47**(Suppl. 2), 1–108.
- Savage, L. (1971) Elicitation of personal probabilities and expectations. *Journal of the American Statistical Association*, **66**, 783–801.
- Schwartz, D., Flamant, R. and Lellouch, J. (1980) *Clinical Trials*. Academic Press, London.
- Sculpher, M., Fenwick, E. and Claxton, K. (2000) Assessing quality in decision-analytic cost-effectiveness models. *Pharmacoeconomics*, **17**, 461–77.

- Selwyn, M. R., Dempster, A. P. and Hall, N. R. (1981) A Bayesian approach to bioequivalence for the 2×2 changeover design. *Biometrics*, **37**, 11–21.
- Selwyn, M. R. and Hall, N. R. (1984) On Bayesian methods for bioequivalence. *Biometrics*, **40**, 1103–8.
- Senn, S. (1996) Some statistical issues in project prioritization in the pharmaceutical industry. *Statistics in Medicine*, **15**, 2689–702.
- Senn, S. (1997a) Statistical basis of public policy – present remembrance of priors past is not the same as a true prior. *British Medical Journal*, **314**, 73.
- Senn, S. (1997b) *Statistical Issues in Drug Development*. John Wiley & Sons, Ltd, Chichester.
- Senn, S. (2002) Ethical considerations concerning treatment allocation in drug development trials. *Statistical Methods in Medical Research*, **11**, 403–11.
- Shachter, R., Eddy, D. M. and Hasselblad, V. (1990) An influence diagram approach to medical technology assessment. In *Influence Diagrams, Belief Nets and Decision Analysis*, (R. M. Oliver and J. Q. Smith, eds), pp. 321–50. John Wiley & Sons, Ltd, Chichester.
- Shakespeare, T. P., Gebski, V. J., Veness, M. J. and Simes, J. (2001) Improving interpretation of clinical studies by use of confidence levels, clinical significance curves, and risk-benefit contours. *Lancet*, **357**, 1349–53.
- Sharp, S. J. and Thompson, S. G. (2000) Analysing the relationship between treatment effect and underlying risk in meta-analysis: comparison and development of approaches. *Statistics in Medicine*, **19**, 3251–74.
- Sheiner, L. (1991) The intellectual health of clinical drug evaluation. *Clinical Pharmacology and Therapeutics*, **50**, 4–9.
- Sheiner, L. and Wakefield, J. (1999) Population modelling in drug development. *Statistical Methods in Medical Research*, **8**, 183–93.
- Shepherd, J., Blauw, G. J., Murphy, M. B., Bollen, E. L. E. M., Buckley, B. M., Cobbe, S. M., Ford, I., Gaw, A., Hyland, M., Jukema, J. W., Kamper, A. M., Macfarlane, P. W., Meinders, A. E., Norrie, J., Packard, C. J., Perry, I. J., Stott, D. J., Sweeney, B. J., Twomey, C. and Westendorp, R. G. J. (2002) Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. *Lancet*, **360**, 1623–30.
- Silliman, N. P. (1997) Hierarchical selection models with applications in meta-analysis. *Journal of the American Statistical Association*, **92**, 926–36.
- Simes, R. J. (1986) Application of statistical decision theory to treatment choices – implications for the design and analysis of clinical trials. *Statistics in Medicine*, **5**, 411–20.
- Simon, R. (1977) Adaptive treatment assignment methods and clinical trials. *Biometrics*, **33**, 743–9.
- Simon, R. (1994a) Problems of multiplicity in clinical trials. *Journal of Statistical Planning and Inference*, **42**, 209–21.
- Simon, R. (1994b). Some practical aspects of the interim monitoring of clinical trials. *Statistics in Medicine*, **13**, 1401–9.
- Simon, R. (2000). Meta-analysis of clinical trials: opportunities and limitations. *Statistical Science*, **15**, 305–20.
- Simon, R. and Freedman, L. S. (1997) Bayesian design and analysis of two \times two factorial clinical trials. *Biometrics*, **53**, 456–64.
- Simon, R., Dixon, D. O., and Friedlin, B. (1996). Bayesian subset analysis of a clinical trial for the treatment of HIV infections. In *Bayesian Biostatistics* (D. A. Berry and D. K. Stangl, eds), pp. 555–76. Marcel Dekker, New York.
- Smith, D., Givens, G. H. and Tweedie, R. L. (2000). Adjustment for publication bias and quality bias in Bayesian meta-analysis. In *Meta-analysis in Medicine and Health Policy* (D. K. Stangl and D. A. Berry, eds), pp. 277–304. Marcel Dekker, New York.

- Smith, T., Spiegelhalter, D. J. and Parmar, M. K. B. (1996). Bayesian meta-analysis of randomized trials using graphical models and BUGS. In *Bayesian Biostatistics* (D. A. Berry and D. K. Stangl, eds), pp. 411–27. Marcel Dekker, New York.
- Smith, T. C., Spiegelhalter, D. J. and Thomas, A. (1995) Bayesian approaches to random-effects meta-analysis: a comparative study. *Statistics in Medicine*, **14**, 2685–99.
- Song, F., Altman, D., Glennie, A.-M. and Deeks, J. J. (2003) Validity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analyses. *British Medical Journal*, **326** (7387), 472–5.
- Souhami, R. L., Craft, A. W., van der Eijken, J., Nooij, M., Spooner, D., Bramwell, V. H. C., Wierzbicki, R., Malcolm, A. J., Kirkpatrick, A., Uscinska, B. M., Van Glabbeke, M. and Machin, D. (1997). Randomised trial of two regimens of chemotherapy in operable osteosarcoma: a study of the European Osteosarcoma Intergroup. *Lancet*, **350** (9082), 911–17.
- Spiegelhalter, D. J. (1998) Bayesian graphical modelling: a case-study in monitoring health outcomes. *Applied Statistics*, **47**, 115–33.
- Spiegelhalter, D. (2001) Bayesian methods for cluster randomized trials with continuous responses. *Statistics in Medicine*, **20**, 435–52.
- Spiegelhalter, D. J. and Best, N. G. (2003) Bayesian methods for evidence synthesis and complex cost-effectiveness models: an example in hip prostheses. *Statistics in Medicine*, In press.
- Spiegelhalter, D. J. and Freedman, L. S. (1986) A predictive approach to selecting the size of a clinical trial, based on subjective clinical opinion. *Statistics in Medicine*, **5**, 1–13.
- Spiegelhalter, D. J., Freedman, L. S. and Blackburn, P. R. (1986) Monitoring clinical trials: conditional or predictive power? *Controlled Clinical Trials*, **7**, 8–17.
- Spiegelhalter, D. J., Freedman, L. S. and Parmar, M. K. B. (1993) Applying Bayesian ideas in drug development and clinical trials. *Statistics in Medicine*, **12**, 1501–17.
- Spiegelhalter, D. J., Freedman, L. S. and Parmar, M. K. B. (1994) Bayesian approaches to randomized trials (with discussion). *Journal of the Royal Statistical Society, Series A*, **157**, 357–416.
- Spiegelhalter, D., Myles, J., Jones, D. and Abrams, K. (2000) Bayesian methods in health technology assessment: a review. *Health Technology Assessment*, **4**(38), 1–130.
- Stallard, N. (1998) Sample size determination for phase II clinical trials based on Bayesian decision theory. *Biometrics*, **54**, 279–94.
- Stangl, D. K. (1996). Hierarchical analysis of continuous-time survival models. In *Bayesian Biostatistics* (D. A. Berry and D. K. Stangl, eds), pp. 429–50. Marcel Dekker, New York.
- Stangl, D. K. and Berry, D. A. (1998) Bayesian statistics in medicine: where we are and where we should be going. *Sankhyā, Series B*, **60**, 176–95.
- Stangl, D. K. and Berry, D. A. (eds) (2000). *Meta-analysis in Medicine and Health Policy*. Marcel Dekker, New York.
- Stangl, D. K. and Greenhouse, J. B. (1998). Assessing placebo response using Bayesian hierarchical survival models. *Lifetime Data Analysis*, **4**, 5–28.
- Stijnen, T. and Van Houwelingen, J. C. (1990). Empirical Bayes methods in clinical trials meta-analysis. *Biometrical Journal*, **32**, 335–46.
- Strauss, N. and Simon, R. (1995). Investigating a sequence of randomized phase II trials to discover promising treatments. *Statistics in Medicine*, **14**, 1479–89.
- Stroup, D. F., Berlin, J. A., Morton, S. C., Olkin, I., Williamson, G. D., Rennie, D., Moher, D., Becker, B. J., Sipe, T. A. and Thacker, S. B. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. *Journal of the American Medical Association*, **283**, 2008–12.
- Su, X. Y. and Po, A. L. W. (1996) Combining event rates from clinical trials: comparison of Bayesian and classical methods. *Annals of Pharmacotherapy*, **30**, 460–5.

- Sutton, A. and Abrams, K. R. (2001) Bayesian methods in meta-analysis and evidence synthesis. *Statistical Methods in Medical Research*, **10**, 277–303.
- Sutton, A., Abrams, K. R., Jones, D. R., Sheldon, T. A. and Song, F. (2000) *Methods for Meta-analysis in Medical Research*. John Wiley & Sons, Ltd, Chichester.
- Sutton, A., Abrams, K. R. and Jones, D. R. (2002) Generalized synthesis of evidence and the threat of dissemination bias: the example of electronic fetal heart rate monitoring (EFM). *Journal of Clinical Epidemiology*, **55**, 1013–24.
- Tamura, R. N., Faries, D. E., Andersen, J. S. and Heiligenstein, J. H. (1994) A case study of an adaptive clinical trial in the treatment of out-patients with depressive disorder. *Journal of the American Statistical Association*, **89**, 768–76.
- Tan, S., Machin, D., Tai, B. C., Foo, K. F. and Tan, E. H. (2002) A Bayesian re-assessment of two phase II trials of gemcitabine in metastatic nasopharyngeal cancer. *British Journal of Cancer*, **86**, 843–50.
- Tan, S. B., Chung, Y. F. A., Tai, B. C., Cheung, Y. B. and Machin, D. (2003) Elicitation of prior distributions for a phase III randomized controlled trial of adjuvant therapy with surgery for hepatocellular carcinoma. *Controlled Clinical Trials*, **24**, 110–21.
- Tarone, R. (1982) The use of historical control information in testing for a trend in proportions. *Biometrics*, **38**, 215–20.
- Ten Centre Study Group (1987) Ten centre study of artificial surfactant (artificial lung expanding compound) in very premature babies. *British Medical Journal*, **294**, 991–6.
- Teo, K. K., Yusuf, S., Collins, R., Held, P. H. and Peto, R. (1991) Effects of intravenous magnesium in suspected acute myocardial infarction: overview of randomised trials. *British Medical Journal*, **303**(6816), 1499–1503.
- Thall, P. F. and Estey, E. H. (1993) A Bayesian strategy for screening cancer treatments prior to phase II clinical evaluation. *Statistics in Medicine*, **12**, 1197–1211.
- Thall, P. F. and Russell, K. E. (1998) A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/ II clinical trials. *Biometrics*, **54**, 251–64.
- Thall, P. F. and Simon, R. (1990) Incorporating historical control data in planning phase II studies. *Statistics in Medicine*, **9**, 215–28.
- Thall, P. F. and Sung, H. (1998) Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials. *Statistics in Medicine*, **17**, 1563–80.
- Thall, P. F., Simon, R. M. and Estey, E. H. (1996) New statistical strategy for monitoring safety and efficacy in single-arm clinical trials. *Journal of Clinical Oncology*, **14**, 296–303.
- Thompson, S. G., Smith, T. C. and Sharp, S. J. (1997) Investigating underlying risk as a source of heterogeneity in meta-analysis. *Statistics in Medicine*, **16**, 2741–58.
- Tsiatis, A. A. (1981) The asymptotic joint distribution of the efficient scores test for the proportional hazards model calculated over time. *Biometrika*, **68**, 311–15.
- Tukey, J. (1977). Some thoughts on clinical trials, especially problems of multiplicity. *Science*, **198**, 679–84.
- Tunis, S. R., Sheinhait, I. A., Schmid, C. H., Bishop, D. J. and Ross, S. D. (1997) Lansoprazole compared with histamine(2)-receptor antagonists in healing gastric ulcers: a meta-analysis. *Clinical Therapeutics*, **19**, 743–57.
- Turner, R., Omar, R. and Thompson, S. (2001) Bayesian methods of analysis for cluster randomized trials with binary outcome data. *Statistics in Medicine*, **20**, 453–72.
- Tversky, A. (1974). Assessing uncertainty. *Journal of the Royal Statistical Society, Series B*, **36**, 148–59.
- Tweedie, R. L., Scott, D. J., Biggerstaff, B. J. and Mengersen, K. L. (1996) Bayesian meta-analysis, with application to studies of ETS and lung cancer. *Lung Cancer*, **14**, S171–94.
- University Group Diabetes Program (1970) A study of the effects of hypoglycemic agents on vascular complications in patients with adult onset diabetes. *Diabetes*, **19** (Suppl. 2), 747–830.

- Urbach, P. (1993) The value of randomization and control in clinical trials. *Statistics in Medicine*, **12**, 1421–31.
- US Food and Drug Administration (1998a) Semiannual guidance agenda. *Federal Register*, **63** (212), 59 317–26.
- US Food and Drug Administration (1998b) *Transcript of Cardiovascular and Renal Drugs Advisory Committee meeting, 26th June 1997*. <http://www.fda.gov/ohrms/dockets/ac/97/transcpt/3320t1.pdf>.
- US Food and Drug Administration (1999a) *Guidance for Industry: Population Pharmacokinetics*. <http://www.fda.gov/cder/guidance/index.htm>.
- US Food and Drug Administration (1999b) *Summary of Safety and Effectiveness Data for T-Scan Breast Scanner*. <http://www.fda.gov/cdrh/pdf/p970033b.pdf>.
- Vail, A., Hornbuckle, J., Spiegelhalter, D. J. and Thornton, J. G. (2001) Prospective application of Bayesian monitoring and analysis in an ‘open’ randomized clinical trial. *Statistics in Medicine*, **20**, 3777–87.
- van Hout, B. A., Al, M. J., Gordon, G. S. and Rutten, F. F. H. (1994) Costs, effects and C/E-ratios alongside a clinical trial. *Health Economics*, **3**, 309–19.
- van Houwelingen, H. C. (1997) The future of biostatistics: expecting the unexpected. *Statistics in Medicine*, **16**, 2773–84.
- van Houwelingen, H. and Senn, S. (1999) Investigating underlying risk as a source of heterogeneity in meta-analysis by S. G. Thompson, T. C. Smith and S. J. Sharp. *Statistics in Medicine*, **16**, 2741–2758 (1997). *Statistics in Medicine*, **18**, 110–13.
- van Houwelingen, H. C., Zwinderman, K., and Stijnen, T. (1993) A bivariate approach to meta-analysis. *Statistics in Medicine*, **12**, 2272–84.
- Wakefield, J. and Bennett, J. (1996) The Bayesian modeling of covariates for population pharmacokinetic models. *Journal of the American Statistical Association*, **91**, 917–27.
- Wakefield, J. and Walker, S. (1997) A population approach to initial dose selection. *Statistics in Medicine*, **16**, 1135–49.
- Waller, S. E. and Duncan, D. (1969) A Bayes rule for the symmetric multiple comparison problem. *Journal of the American Statistical Association*, **64**, 1484–1503.
- Ware, J. (1989) Investigating therapies of potentially great benefit: ECMO (with discussion). *Statistical Science*, **4**, 298–340.
- Ware, J. H., Muller, J. E. and Braunwald, E. (1985) The futility index: an approach to the cost-effective termination of randomized clinical trials. *American Journal of Medicine*, **78**, 635–43.
- Warn, D. E., Thompson, S. G. and Spiegelhalter, D. J. (2002). Bayesian random effects meta-analysis of trials with binary outcomes: methods for the absolute risk difference and relative risk scales. *Statistics in Medicine*, **21**, 1601–24.
- Weiss, H. L., Urban, D. A., Grizzle, W. E., Cronin, K. A., Freedman, L. S., Kelloff, G. J. and Lieberman, R. (2001) Bayesian monitoring of a phase 2 chemoprevention trial in highrisk cohorts for prostate cancer. *Urology*, **57**, 220–3.
- Wheatley, K. and Clayton, D. (2003) Be skeptical about unexpected large apparent treatment effects: the case of an MRC AML12 randomization. *Controlled Clinical Trials*, **24**, 66–70.
- Whitehead, A. (2002) *Meta-analysis of Controlled Clinical Trials*. John Wiley & Sons, Ltd, Chichester.
- Whitehead, J. (1986) Sample sizes for phase-II and phase-III clinical trials – an integrated approach. *Statistics in Medicine*, **5**, 459–64.
- Whitehead, J. (1993) The case for frequentism in clinical trials. *Statistics in Medicine*, **12**, 1405–19.
- Whitehead, J. (1997a) Bayesian decision procedures with application to dose-finding studies. *International Journal of Pharmaceutical Medicine*, **11**(4), 201–7.

- Whitehead, J. (1997b) *The Design and Analysis of Sequential Clinical Trials* (2nd edition). John Wiley & Sons, Ltd, Chichester.
- Whitehead, J. and Brunier, H. (1995) Bayesian decision procedures for dose determining experiments. *Statistics in Medicine*, **14**, 885–93.
- Willan, A. R. (2001) On the probability of cost-effectiveness using data from randomised clinical trials. *BMC Medical Research Methodology*, **1**(8). <http://biomedcentral.com/1471-2288/1/8>.
- Woods, K. L., Fletcher, S., Roffe, C. and Haider, Y. (1992) Intravenous magnesium sulphate in suspected acute myocardial infarction: results of the Second Leicester Intravenous Magnesium Intervention Trial (LIMIT-2). *Lancet*, **339** (8809), 1553–8.
- Yao, T. J., Begg, C. B. and Livingston, P. O. (1996) Optimal sample size for a series of pilot trials of new agents. *Biometrics*, **52**, 992–1001.
- Yusuf, S. (1997) Meta-analysis of randomised trials: Looking back and looking again. *Controlled Clinical Trials*, **18**, 594–601.
- Yusuf, S., Teo, K. and Woods, K. (1993) Intravenous magnesium in acute myocardial infarction: an effective, safe, simple and inexpensive treatment. *Circulation*, **87**, 2043–6.
- Zelen, M. (1969) Play the winner rule and the controlled clinical trial. *Journal of the American Statistical Association*, **64**, 131–46.
- Zelen, M. (1990) Discussion of 'Biostatistics and Bayes' by Breslow. *Statistical Science*, **5** (3).
- Zelen, M. and Parker, R. A. (1986) Case control studies and Bayesian inference. *Statistics in Medicine*, **5**, 261–9.
- Zucker, D. R., Schmid, C. H., McIntosh, M. W., Agostino, R. B., Selker, H. P. and Lau, J. (1997) Combining single patient (n -of-1) trials to estimate population treatment effects and to evaluate individual patient responses to treatment. *Journal of Clinical Epidemiology*, **50**, 401–10.